Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Key Highlights
- ➤Robert Bitterman to present Phio’s INTASYL siRNA platform October 20, 2026
- ➤PH-762 is Phio’s lead clinical candidate for cutaneous carcinomas
- ➤Phase 1b trial evaluated PH-762 in three skin cancers
- ➤Phio expects next-phase development activities completed during first quarter of 2027
Expert Statements
Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals
“We look forward to engaging with investors at the Renmark Financial Virtual Non-Deal Roadshow to highlight Phio's differentiated siRNA therapeutic platform which is designed to offer a unique and promising approach to advancing immuno-oncology therapies”
Live Presentation and Q&A: Tuesday, October 20, 2026 12 PM EDT
King of Prussia, Pennsylvania--(Newsfile Corp. - October 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL(®) gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL(®) siRNA therapeutic platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas. The presentation will be followed by a live Q&A session.
Get started
Create a free account to read the full story.